```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.88       1.09

FILE 'CAPLUS' ENTERED AT 19:40:57 ON 19 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 19 Feb 2006  VOL 144 ISS 9
FILE LAST UPDATED: 17 Feb 2006  (20060217/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3            7 L2

=> d l3 5-7 bib abs hitstr

L3   ANSWER 5 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2002:575065  CAPLUS
DN   137:140776
TI   Preparation of piperidinyl and piperazinyl amino acid derivatives as
     melanocortin receptor agonists
IN   Backer, Ryan Thomas; Briner, Karin; Doecke, Christopher William; Fisher,
     Matthew Joseph; Kuklish, Steven Lee; Mancuso, Vincent; Martinelli, Michael
     John; Mullaney, Jeffrey Thomas; Xie, Chaoyu
PA   Eli Lilly and Company, USA
SO   PCT Int. Appl., 263 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   WO 2002059107        A1    20020801    WO 2002-US516            20020123
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
```

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2433025	AA	20020801	CA 2002-2433025	20020123
	EP 1368339	A1	20031210	EP 2002-701923	20020123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004521117	T2	20040715	JP 2002-559409	20020123
	US 2004058936	A1	20040325	US 2003-466249	20030711
PRAI	US 2001-263595P	P	20010123		
	WO 2002-US516	W	20020123		

OS CASREACT 137:140776; MARPAT 137:140776

GI



I

AB The invention relates to melanocortin receptor (MC-R) agonists I [G = CR1 or N; LL1 = H2 or oxo; T = isoquinolinyl or tetrahydro deriv., isoindolinyl, or piperazinyl; n = 0-8; R = H, OH, CN, NO2, halo, alkyl, acyl, etc.; R1 = H, alkyl, alkylcarbamoyl, (D)phenyl, (D)cycloalkyl, or oxo (unless amide is formed); p = 0-4; CR2CR2 is a 5- or 6-membered carbocycle optionally substituted by 1-3 groups R; R3 = (un)substituted aryl or thienyl; R4 = H, alkyl, acyl, cycloalkyl, or alkoxyalkyl], or their pharmaceutically-acceptable salts or stereoisomers, which are useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction. Compds. I comprise three domains, i.e., a piperidino or piperazinyl fragment, an amino acid, and a radical CLL1(CH2)n-T. Thus, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [1-(4-chlorobenzyl)-2-[4-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl]piperazin-1-yl]-2-oxoethyl]amide (claimed compd.) was prepd. via acylation of the piperazine moiety.

IT **444619-63-0P 444619-65-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperidinyl and piperazinyl amino acid derivs. as melanocortin receptor agonists)

RN 444619-63-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-oxo-2-[4-[1,2,3,4-tetrahydro-2-(phenylsulfonyl)-8-isoquinolinyl]-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444619-65-2 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[4-(2-benzoyl-1,2,3,4-tetrahydro-8-isoquinolinyl)-1-piperazinyl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **444620-47-7P 444620-49-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperidinyl and piperazinyl amino acid derivs. as melanocortin receptor agonists)
RN 444620-47-7 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 444620-49-9 CAPLUS
CN Isoquinoline, 2-benzoyl-1,2,3,4-tetrahydro-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:742072 CAPLUS
DN 133:309907
TI Preparation of nitrogen-containing heterocyclic compounds and benzamide compounds as hypolipidemics and antiarteriosclerotics
IN Ohkura, Naoto; Hiraiwa, Yukiko; Matsushima, Tetsuya; Sasaki, Kazue; Yamamoto, Takehiro; Shiotani, Masaharu; Suzuki, Shigeki; Nakatani, Yuuko; Kuroda, Chizuko; Nagasawa, Mieko; Katano, Kiyoaki
PA Meiji Seika Kaisha, Ltd., Japan
SO PCT Int. Appl., 284 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000061556	A1	20001019	WO 2000-JP2329	20000410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2369103	AA	20001019	CA 2000-2369103	20000410
BR 2000009650	A	20020102	BR 2000-9650	20000410
EP 1180514	A1	20020220	EP 2000-915465	20000410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 779550	B2	20050127	AU 2000-36759	20000410
US 6777414	B1	20040817	US 2001-958296	20011005
US 2004224959	A1	20041111	US 2004-868006	20040616

PRAI JP 1999-102559 A 19990409
JP 1999-118490 A 19990426
JP 1999-119043 A 19990427
WO 2000-JP2329 W 20000410
US 2001-958296 A3 20011005

OS MARPAT 133:309907

GI



I



II

AB The title compds. [I; R1 and R2 represent each (un)substituted C1-6 alkyl or alkoxy, C3-8 cycloalkyl, Ph, C2-6 alkenyl or alkynyl, 5- or 6-membered ring (un)satd. heterocyclyl; R3 and R4 represent each hydrogen, (un)substituted C1-6 alkyl, halo, OH, cyano, C2-5 alkoxycarbonyl, C1-6 alkoxy, or CO2H ; or R2 and R3 may be bonded to each other to form (CH2)m, N:CH, CH:N, or (C1-6 alkyl)-C:N; wherein m is 1 or 2; A, D, E and G represent each C, or one of A, D, E and G represents N and the remainders represent C; Q represents N or C; Y represents a group represented by general formula Q1 (wherein X represents hydrogen, CONR5R6, etc.; R8 represents nil or a bond, O, etc.; and R9 and R10 represent each hydrogen, alkyl, etc.); and Z represents (CH2)n, O(CH2)i, or CONH(CH2)i; wherein n is 0-6; i is 1-6] are prepd. These compds. have an effect of inhibiting the biosynthesis of triglycerides in the liver and an effect of inhibiting the secretion of apolipoprotein B-contg. lipoproteins from the liver (the latter effect being particularly excellent), without showing the side effect of fat accumulation in the liver, and are useful in treating and preventing hyperlipemia, arteriosclerotic diseases, and pancreatitis.

Thus, to a soln. of 2-benzyl-7-[4-[4-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]butyl]piperazin-1-yl]-3,4-dihydro-2H-isoquinolin-1-one in PhMe were added NaOH, K2CO3, tetrabutylammonium hydrogen sulfate, and allyl bromide and the resulting mixt. was stirred at 60.degree. overnight to give title compd. (II). II in vitro inhibited the secretion of apolipoprotein B by 89% and the biosynthesis of triglycerides by 89% in HepG2 cells. Tablet and capsule formulations were also described.

IT **301666-52-4P 301666-53-5P 301667-25-4P**
301667-28-7P 301667-33-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. and benzamide compds. as hypolipidemics and antiarteriosclerotics and inhibitors of apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)

RN 301666-52-4 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301666-53-5 CAPLUS
CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-25-4 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-28-7 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-1-piperazinyl]propyl]-N-(2,2,2-

trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-33-4 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[8-chloro-1,2,3,4-tetrahydro-2-[(3-methoxyphenyl)methyl]-1-oxo-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **217492-19-8P 301667-26-5P 301667-27-6P 301667-35-6P 301667-36-7P 301667-53-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nitrogen-contg. heterocyclic compds. and benzamide compds. as hypolipidemics and antiarteriosclerotics and inhibitors of apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)

RN 217492-19-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 301667-26-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 301667-27-6 CAPLUS
CN 1(2H)-Isoquinolinone, 3,4-dihydro-7-(1-piperazinyl)-2-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)



RN 301667-35-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[8-chloro-1,2,3,4-tetrahydro-2-[(3-methoxyphenyl)methyl]-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 301667-36-7 CAPLUS
CN 1(2H)-Isoquinolinone, 8-chloro-3,4-dihydro-2-[(3-methoxyphenyl)methyl]-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 301667-53-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-6-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:793126 CAPLUS
DN 130:52434
TI Prepn. of nitrogenous heterocyclic compounds as hyperlipemia remedies
IN Ohkura, Naoto; Tsuruoka, Takashi; Usui, Takayuki; Hiraiwa, Yukiko; Matsushima, Tetsuya; Shiotani, Masaharu; Niizato, Tetsutaro; Nakatani, Yuuko; Suzuki, Shigeki; Kuroda, Chidsuko; Katano, Kiyoaki
PA Meiji Seika Kaisha, Ltd., Japan; et al.

SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9854135	A1	19981203	WO 1998-JP2411	19980601
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2291630	AA	19981203	CA 1998-2291630	19980601
AU 9875482	A1	19981230	AU 1998-75482	19980601
EP 999208	A1	20000510	EP 1998-923066	19980601
R: DE, ES, FR, GB, IT				
US 6417362	B1	20020709	US 1999-424708	19991130
US 2002156276	A1	20021024	US 2002-127491	20020423
US 6583144	B2	20030624		
PRAI JP 1997-141410	A	19970530		
WO 1998-JP2411	W	19980601		
US 1999-424708	A3	19991130		

OS MARPAT 130:52434
GI



I



II

AB The title compds. [I; A = CR1R2(CH2)i; (wherein R1 and R2 each represents hydrogen or alkyl, i = 0-1), CH:CH, OCH2, or S(O)jCH2 (wherein j = 0-2); B = hydrogen or halogen; X = CR3R4R5, NR6R7, (CH2CH:C(CH3)CH2)pCH2CH:C(CH3)2, alkyl, cycloalkyl, Ph, cinnamyl, or heteroaryl; Y = (CH2)q, CH:CH, NR8, oxygen, or a bond; Z = carbonyl or a bond; K = alkylene or a bond; L = CH:CH or a bond; and M = hydrogen, alkyl, cycloalkyl, Ph, heterocycle, biphenyl, or diphenymethyl; p = 0-2; q = 1-6; R3-R5 = hydrogen, phenyl;

R6-R7 = hydrogen, Ph, benzyl; R8 = hydrogen, C1-6 alkyl] are prepd. I inhibit the biosynthesis of triglycerides in the liver and also inhibit the secretion of lipoproteins contg. apolipoprotein B from the liver. I are hence useful for the prevention/treatment of hyperlipemia (esp. hyper-VLDL-emia) and diseases caused thereby, such as arteriosclerotic diseases, e.g., myocardial infarct, and pancreatitis. Thus, title compd. (II) was prepd. by multi-step reactions and showed 56% and 90% inhibitory activity for apolipoprotein B and triglycerides. A formulation contg. I was also presented.

IT **217492-19-8P 217492-20-1P 217492-23-4P**
217492-24-5P 217492-25-6P 217492-26-7P
217492-28-9P 217492-29-0P 217492-31-4P
217492-32-5P 217492-38-1P 217492-40-5P
217492-65-4P 217492-67-6P 217492-69-8P
217492-70-1P 217492-71-2P 217492-72-3P
217492-73-4P 217492-74-5P 217492-75-6P
217492-76-7P 217492-77-8P 217492-78-9P
217492-79-0P 217492-80-3P 217492-81-4P
217492-82-5P 217492-83-6P 217492-84-7P
217492-85-8P 217492-86-9P 217492-87-0P
217492-88-1P 217492-90-5P 217492-91-6P
217492-92-7P 217492-93-8P 217492-94-9P
217492-95-0P 217492-96-1P 217492-98-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogenous heterocyclic compds. as hyperlipemia remedies)

RN 217492-19-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 217492-20-1 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-23-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(cyclohexylmethyl)-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 217492-24-5 CAPLUS
CN 1(2H)-Isoquinolinone, 2-(cyclohexylmethyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-25-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(cyclopropylmethyl)-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 217492-26-7 CAPLUS
CN 1(2H)-Isoquinolinone, 2-(cyclopropylmethyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-28-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 217492-29-0 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(4-chlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-31-4 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(2-chlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-32-5 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(3-chlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-38-1 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(4,4-diphenylbutyl)-1-piperazinyl]-3,4-dihydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-40-5 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-3,4-dihydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-65-4 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 217492-67-6 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 217492-69-8 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 217492-70-1 CAPLUS
CN 1(2H)-Isoquinolinone, 2-(3,3-diphenylpropyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-71-2 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-72-3 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-73-4 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-74-5 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(3,4-dimethylphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-75-6 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(2,5-dimethylphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-76-7 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-77-8 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 217492-78-9 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 217492-79-0 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 217492-80-3 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-2-[(3-fluorophenyl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-81-4 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(3-bromophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-82-5 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(3,4-dichlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-83-6 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(2,4-dichlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-84-7 CAPLUS
CN Benzoic acid, 4-[[7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 217492-85-8 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-86-9 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(3,5-dimethoxyphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-87-0 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-88-1 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[(3,5-dihydroxyphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-90-5 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-hydroxy-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 217492-91-6 CAPLUS
CN 1(2H)-Isoquinolinone, 2-([1,1'-biphenyl]-2-ylmethyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-92-7 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-93-8 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-94-9 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(4-methyl-5-thiazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 217492-95-0 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-96-1 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-98-3 CAPLUS
CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-4,4-dimethyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.25	17.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:42:00 ON 19 FEB 2006